Celldex Therapeutics Inc. (CLDX): Today's Featured Drugs Laggard

Celldex Therapeutics was a leading decliner within the drugs industry, falling $0.40 (-2.0%) to $19.55 on average volume
By TheStreet Wire ,

Celldex Therapeutics

(

CLDX

) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.3%. By the end of trading, Celldex Therapeutics fell $0.40 (-2.0%) to $19.55 on average volume. Throughout the day, 1,715,986 shares of Celldex Therapeutics exchanged hands as compared to its average daily volume of 1,860,800 shares. The stock ranged in price between $19.20-$20.33 after having opened the day at $20.23 as compared to the previous trading day's close of $19.95. Other companies within the Drugs industry that declined today were:

Mast Therapeutics

(

MSTX

), down 34.5%,

Merrimack Pharmaceuticals

(

MACK

), down 28.0%,

Inovio Pharmaceuticals

(

INO

), down 11.6% and

CytRx Corporation

(

CYTR

), down 8.1%.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Celldex Therapeutics has a market cap of $1.6 billion and is part of the health care sector. Shares are up 197.3% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates

Celldex Therapeutics

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow.

On the positive front,

Rexahn Pharmaceuticals

(

RNN

), up 16.8%,

Alnylam Pharmaceuticals

(

ALNY

), up 15.8%,

Rockwell Medical

(

RMTI

), up 15.7% and

Bacterin International Holdings

(

BONE

), up 14.9% , were all gainers within the drugs industry with

Vertex Pharmaceuticals

(

VRTX

) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

Loading ...